Pay-for-delay: Play by the rules

On September 8, the EU General Court handed down its judgment in appeal proceedings brought by Danish innovator Lundbeck and a number of generic companies against a 2013 European Commission decision that imposed fines of €146 million ($164 million) on the appellants.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

Pharma

What’s at stake in Australia’s biggest pharma patent appeal in years?

1 July 2026 Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.

More features

Why is 2026 already a record year for M&A activity?

Illumina ordered to recall products after German patent ruling

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

Influential Women in IP 2026: Who made the list?

UPC revives patent, but timing sinks Guardant’s appeal

Pay-for-delay: Play by the rules

More on this story

Editor's picks

Editor's picks

More features